IL132312A0 - Use of leptin in inhibition of endothelial cell proliferation - Google Patents
Use of leptin in inhibition of endothelial cell proliferationInfo
- Publication number
- IL132312A0 IL132312A0 IL13231299A IL13231299A IL132312A0 IL 132312 A0 IL132312 A0 IL 132312A0 IL 13231299 A IL13231299 A IL 13231299A IL 13231299 A IL13231299 A IL 13231299A IL 132312 A0 IL132312 A0 IL 132312A0
- Authority
- IL
- Israel
- Prior art keywords
- leptin
- inhibition
- cell proliferation
- endothelial cell
- endothelial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13231299A IL132312A0 (en) | 1999-09-05 | 1999-10-10 | Use of leptin in inhibition of endothelial cell proliferation |
UA2002042717A UA74163C2 (uk) | 1999-09-05 | 2000-04-09 | Застосування лептину для інгібування ангіогенезу, фармацевтична композиція та спосіб інгібування ангіогенезу у ссавців |
CNB00813748XA CN1189479C (zh) | 1999-09-05 | 2000-09-04 | 应用苗条蛋白抑制内皮细胞增殖 |
BR0013778-2A BR0013778A (pt) | 1999-09-05 | 2000-09-04 | Uso de leptina na inibição de proliferação de célula endotelial |
JP2001522262A JP2003508544A (ja) | 1999-09-05 | 2000-09-04 | 内皮細胞増殖の阻害剤におけるレプチンの用途 |
EA200200331A EA005066B1 (ru) | 1999-09-05 | 2000-09-04 | Применение лептина для ингибирования пролиферации эндотелиальных клеток |
IL14844500A IL148445A0 (en) | 1999-09-05 | 2000-09-04 | Use of leptin in inhibition of endothelial cell proliferation |
DE60043391T DE60043391D1 (de) | 1999-09-05 | 2000-09-04 | Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen |
ES00956758T ES2335569T3 (es) | 1999-09-05 | 2000-09-04 | Uso de leptina junto con un inhibidor de vegf y/o un inhibidor de angiogenesis para la inhibicion de la proliferacion de celulas endonteliales. |
AT00956758T ATE449609T1 (de) | 1999-09-05 | 2000-09-04 | Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen |
CA2382941A CA2382941C (fr) | 1999-09-05 | 2000-09-04 | Utilisation de leptine en vue d'empecher la proliferation de la cellule endotheliale |
PCT/IL2000/000525 WO2001018040A2 (fr) | 1999-09-05 | 2000-09-04 | Utilisation de leptine en vue d'empecher la proliferation de la cellule endotheliale |
MXPA02002448A MXPA02002448A (es) | 1999-09-05 | 2000-09-04 | Uso de leptina en la inhibicion de la poliferacion de la celula endotelial. |
ARP000104622A AR025494A1 (es) | 1999-09-05 | 2000-09-04 | Uso de la leptina, homologos de leptina o derivados de leptina opcionalmente junto con un inhibidor de la accion de vegf o de la sintesis del vegf y/o uninhibidor de la angiogenesis, composiciones farmaceuticas que incluyen leptina, metodo para inhibir reversiblemente la proliferacion de dichas celu |
AU68620/00A AU781390B2 (en) | 1999-09-05 | 2000-09-04 | Use of leptin in inhibition of endothelial cell proliferation |
EP00956758A EP1210108B1 (fr) | 1999-09-05 | 2000-09-04 | Utilisation de la leptine en combinaison avec un inhibiteur de vegf et/ou un inhibiteur de l'angiogenese pour inhiber la proliferation des cellules endotheliales |
EEP200200116A EE05262B1 (et) | 1999-09-05 | 2000-09-04 | Leptiini v?i selle homoloogi v?i derivaadi kasutamine, farmatseutiline kompositsioon ja segu |
KR1020027002112A KR100683362B1 (ko) | 1999-09-05 | 2000-09-04 | 내피세포 증식의 저해에서 렙틴의 용도 |
NO20020920A NO325989B1 (no) | 1999-09-05 | 2002-02-25 | Anvendelse av leptin, i kombinasjon med en hemmer av VEGF og/eller angiogenese, for a hemme angiogenese. |
HK03100442.1A HK1048075B (zh) | 1999-09-05 | 2003-01-17 | 應用苗條蛋白抑制內皮細胞增殖 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13173999A IL131739A0 (en) | 1999-09-05 | 1999-09-05 | Use of leptin in inhibition of endothelial cell proliferation |
IL13231299A IL132312A0 (en) | 1999-09-05 | 1999-10-10 | Use of leptin in inhibition of endothelial cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL132312A0 true IL132312A0 (en) | 2001-03-19 |
Family
ID=26323878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13231299A IL132312A0 (en) | 1999-09-05 | 1999-10-10 | Use of leptin in inhibition of endothelial cell proliferation |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1210108B1 (fr) |
JP (1) | JP2003508544A (fr) |
KR (1) | KR100683362B1 (fr) |
CN (1) | CN1189479C (fr) |
AR (1) | AR025494A1 (fr) |
AT (1) | ATE449609T1 (fr) |
AU (1) | AU781390B2 (fr) |
BR (1) | BR0013778A (fr) |
CA (1) | CA2382941C (fr) |
DE (1) | DE60043391D1 (fr) |
EA (1) | EA005066B1 (fr) |
EE (1) | EE05262B1 (fr) |
ES (1) | ES2335569T3 (fr) |
HK (1) | HK1048075B (fr) |
IL (1) | IL132312A0 (fr) |
MX (1) | MXPA02002448A (fr) |
NO (1) | NO325989B1 (fr) |
UA (1) | UA74163C2 (fr) |
WO (1) | WO2001018040A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355237B1 (en) * | 1994-09-14 | 2002-03-12 | Progenitor, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
US8633250B2 (en) * | 2006-01-12 | 2014-01-21 | Musc Foundation For Research Development | Cell repair and regeneration by suramin and related polysulfonated napthylureas |
EP2455077B1 (fr) * | 2009-06-17 | 2014-06-11 | National University Corporation Kumamoto University | Agent prophylactique et/ou thérapeutique pour dysménorrhée |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4018142B2 (ja) * | 1996-01-23 | 2007-12-05 | インデバス ファーマシューティカルズ,インコーポレーテッド | 造血発生を刺激するためのobese遺伝子およびその産物の使用方法 |
IT1288388B1 (it) * | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
IL120733A0 (en) * | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
WO1999059614A1 (fr) * | 1998-05-20 | 1999-11-25 | Yale University | Modulation de l'angiogenese et de la cicatrisation |
-
1999
- 1999-10-10 IL IL13231299A patent/IL132312A0/xx unknown
-
2000
- 2000-04-09 UA UA2002042717A patent/UA74163C2/uk unknown
- 2000-09-04 EA EA200200331A patent/EA005066B1/ru not_active IP Right Cessation
- 2000-09-04 KR KR1020027002112A patent/KR100683362B1/ko not_active IP Right Cessation
- 2000-09-04 AR ARP000104622A patent/AR025494A1/es unknown
- 2000-09-04 CA CA2382941A patent/CA2382941C/fr not_active Expired - Fee Related
- 2000-09-04 AT AT00956758T patent/ATE449609T1/de not_active IP Right Cessation
- 2000-09-04 WO PCT/IL2000/000525 patent/WO2001018040A2/fr active IP Right Grant
- 2000-09-04 CN CNB00813748XA patent/CN1189479C/zh not_active Expired - Fee Related
- 2000-09-04 EP EP00956758A patent/EP1210108B1/fr not_active Expired - Lifetime
- 2000-09-04 MX MXPA02002448A patent/MXPA02002448A/es active IP Right Grant
- 2000-09-04 AU AU68620/00A patent/AU781390B2/en not_active Ceased
- 2000-09-04 EE EEP200200116A patent/EE05262B1/xx not_active IP Right Cessation
- 2000-09-04 BR BR0013778-2A patent/BR0013778A/pt not_active Application Discontinuation
- 2000-09-04 DE DE60043391T patent/DE60043391D1/de not_active Expired - Lifetime
- 2000-09-04 ES ES00956758T patent/ES2335569T3/es not_active Expired - Lifetime
- 2000-09-04 JP JP2001522262A patent/JP2003508544A/ja active Pending
-
2002
- 2002-02-25 NO NO20020920A patent/NO325989B1/no not_active IP Right Cessation
-
2003
- 2003-01-17 HK HK03100442.1A patent/HK1048075B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60043391D1 (de) | 2010-01-07 |
EE05262B1 (et) | 2010-02-15 |
CN1189479C (zh) | 2005-02-16 |
ATE449609T1 (de) | 2009-12-15 |
NO20020920L (no) | 2002-05-03 |
NO325989B1 (no) | 2008-09-01 |
CA2382941C (fr) | 2011-08-16 |
HK1048075B (zh) | 2005-07-29 |
KR100683362B1 (ko) | 2007-02-15 |
EP1210108B1 (fr) | 2009-11-25 |
KR20020040781A (ko) | 2002-05-30 |
ES2335569T3 (es) | 2010-03-30 |
EE200200116A (et) | 2003-04-15 |
MXPA02002448A (es) | 2002-07-30 |
AR025494A1 (es) | 2002-11-27 |
UA74163C2 (uk) | 2005-11-15 |
EA005066B1 (ru) | 2004-10-28 |
HK1048075A1 (en) | 2003-03-21 |
AU781390B2 (en) | 2005-05-19 |
NO20020920D0 (no) | 2002-02-25 |
WO2001018040A3 (fr) | 2001-06-14 |
BR0013778A (pt) | 2002-05-14 |
AU6862000A (en) | 2001-04-10 |
JP2003508544A (ja) | 2003-03-04 |
EA200200331A1 (ru) | 2002-08-29 |
CA2382941A1 (fr) | 2001-03-15 |
CN1377277A (zh) | 2002-10-30 |
EP1210108A2 (fr) | 2002-06-05 |
WO2001018040A2 (fr) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1526132E (pt) | Derivados de oxazolidinona substituídos e sua utilização enquanto inibidores do factor xa | |
IL144214A0 (en) | Benzoheterocycles and their use as mek inhibitors | |
IL148698A0 (en) | INHIBITORS OF FACTOR Xa | |
HK1045299B (zh) | 細胞增殖抑制劑 | |
IL149374A0 (en) | New use and novel n-azabicyclo-amide derivatives | |
IL144668A0 (en) | The use of 4-h-1-benzopyran-4- one derivatives as inhibitors of smooth muscle cell proliferation | |
IL190220A0 (en) | Novel composition and use | |
HUP0200549A3 (en) | Apomorphine and sildenafil composition and their use | |
AU1939801A (en) | In situ bioreactors and methods of use thereof | |
AU4340700A (en) | Methods and compositions for use in the treatment of hyperlipidemia | |
HUP0203896A3 (en) | Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof | |
HU0001396D0 (en) | 3-amino-3-arylpropan-1-al derivatives and their use | |
IL143987A0 (en) | New amidinobenzylamine derivatives and their use as thrombin inhibitors | |
EG22491A (en) | Rest-breaking composition and use thereof | |
IL132312A0 (en) | Use of leptin in inhibition of endothelial cell proliferation | |
IL148445A0 (en) | Use of leptin in inhibition of endothelial cell proliferation | |
IL131739A0 (en) | Use of leptin in inhibition of endothelial cell proliferation | |
HK1054385A1 (en) | Substituted bisindolylmaleimides for the inhibition of cell proliferation | |
GB9911606D0 (en) | Composition and use | |
AU4025100A (en) | Immortal microvascular endothelial cells and uses thereof | |
GB9929581D0 (en) | Comjpositions and their use | |
AU2045601A (en) | Methods and agents for the inhibition of smooth muscle cell proliferation | |
SI1150996T1 (sl) | Novi amidinobenzilaminski derivati in njihova uporaba kot trombinski inhibitorji | |
SI1233964T1 (en) | New use and novel n-azabicyclo-amide derivatives | |
SI1163208T1 (en) | Caspase inhibitors and uses thereof |